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ABSTRACT 
THE USE OF MICHAELIS-ARBUZOV CHEMISTRY TO SYNTHESIZE A LIBRARY 
OF NOVEL PHOSPHONAMIDE INHIBITORS OF METALLO-β-LACTAMASES 
By 
Stacie Stuut 
University of New Hampshire, September 2019 
 As a result of the constant overuse and misuse of antibiotics, bacteria have 
developed a variety of resistance mechanisms against them. One of the most effective 
forms of resistance are β-lactamase enzymes that work by hydrolyzing β-lactam antibiotics. 
There are four classes of β-lactamase enzymes: A, B, C and D. Class B enzymes, also 
known as metallo-β-lactamases (MBLs), are unique because they contain one or two Zn(II) 
ions in their active site. In order to combat these enzymes, scientists have developed 
inhibitors to be co-prescribed with already known antibiotics. The inhibitors preferentially 
bind to the β-lactamases while the antibiotics are able to kill the bacteria. Unfortunately, 
there are no known clinical inhibitors for MBLs, which have been known to hydrolyze last 
resort antibiotics. Our goal is to synthesize a library of novel phosphonamide compounds 
to be used as possible MBL inhibitors. 
 A four-step synthetic strategy to synthesize the phosphonamide compounds was 
designed and optimized. Arbuzov chemistry was used to form a library of six compounds 
with varying functional groups. Optimal monodealkylation techniques were investigated; 
these included the use of NaOH, LiBr, NaI, and t-BuNH2. Running the reaction with NaOH 
yielded pure, desired products in the highest yields. The most effective reaction conditions 
for the chlorination reactions were determined and each phosphonochloridate was reacted 
 xiv 
with D-Proline ethyl ester · HCl to form the target compounds. phosphonamide, P-[(2-(4-
morpholinyl)ethyl-D-proline ethyl ester]-, monoethyl ester (6) was isolated as a 1:1 
mixture of diastereomers in a 74% yield, which is the highest among the final compounds. 
phosphonamide, P-[vinyl-D-proline ethyl ester]-, monoethyl ester (7), phosphonamide, P-
[(pentafluorophenyl)methyl-D-proline ethyl ester]-, monoethyl ester (10) and phosphonic 
acid, P-[[4-(trifluoromethyl)phenyl]methyl-D-proline ethyl ester]-, monoethyl ester (11) 
were formed in 17, 20 and 15% yields respectively. Unlike 7 and 10, target compound 11 
was isolated as a single diastereomer. phosphonamide, P-[(3-nitrophenyl)methyl-D-
proline ethyl ester]-, monoethyl ester (8) and phosphonamide, P-[ethyl-D-proline ethyl 
ester]-, monoethyl ester (9) were also a mixture of diastereomers and were made in yields 
of 33 and 47% respectively. The structures of the final compounds were confirmed using 
1H, 13C, and 31P NMR as well as numerous 2D NMR studies. They were further analyzed 
using high resolution electron spray ionization mass spectrometry (ESI-MS). The 
optimized synthetic strategy can be used to produce more final products and further expand 




Chapter 1: Introduction 
 
  Due to the extensive use and misuse of antimicrobials, like antibiotics, 
antimicrobial resistant (AMR) bacterial infections are quickly becoming one of the largest 
global public health threats. An estimated 700,000 deaths every year are a direct result of 
AMR, and the World Health Organization (WHO) expects this number to increase to 
approximately 10 million deaths per year by 2050.1,2 In addition to the drastic increase in 
mortality rates, the financial burden is enormous. Current approximations show the US 
spends more than 20 billion dollars in excess healthcare costs each year due to AMR, and 
the WHO predicts the cumulative costs will reach 100 trillion dollars by the year 2050.3 In 
order to reduce the death toll and economic cost, it is imperative that scientists focus on 
combatting the ever-growing threat of AMR infections, and one way of doing this is 
through improving the effectiveness of existing antibiotics such as β-lactam antibiotics. 
β-lactam antibiotics are the most commonly prescribed class of antibiotics and 
include penicillins, cephalosporins, monobactams, and carbapenems (Figure 1). These 
compounds all contain a β-lactam ring: a strained, four-membered ring containing an amide 
functional group. This lactam ring contributes to the high efficacy of the drug and allows 
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 2 
it to target transpeptidase enzymes, also called penicillin-binding proteins (PBPs) that 
catalyze the crosslinking of the bacterial cell wall.4 Once the drug binds to the active site, 
the enzyme can no longer continue the crosslinking, and the wall begins to weaken. As the 
bacteria grow, the cells burst, and the bacteria die. Due to the frequency of β-lactam 
prescription, bacteria mutate and develop resistance mechanisms against these drugs.5 
One of the most effective resistance mechanisms of the bacteria is the expression 
of β-lactamase enzymes that specifically target β-lactam antibiotics. There are four classes 
of β-lactamases: A, B, C and D.7 Classes A, C and D have a serine residue in their active 
site and catalyze hydrolysis of the antibiotic through the mechanism outlined in Scheme 1. 
The antibiotic binds to the active site and the enzyme hydrolyzes the amide linkage of the 
β-lactam ring and forms a tetrahedral intermediate. Next, a water molecule attacks the 
carbonyl and breaks the bond between the enzyme and the drug. The hydrolyzed antibiotic 












































is no longer able to bind to the PBPs and the integrity of the bacterial cell wall is 
unaffected.8,9  
 Class B β-lactamases, also called metallo-β-lactamases (MBLs), contain one or two 
Zn(II) ions in their active site (Scheme 2). These ions coordinate to an activated water 
molecule and position it to attack the carbonyl on the lactam ring.9 Once the hydroxide ion 
attacks and the amide bond is broken, the Zn(II) ions stabilize the hydrolyzed antibiotic 
until it leaves the active site. New Delhi metallo-β-lactamase-1 (NDM-1) is an aggressive 
class B β-lactamase that hydrolyzes carbapenems, which are considered last resort 
antibiotics.9 Healthcare professionals are quickly running out of effective antibacterial 
treatments to cure infections caused by bacteria that express NDM-1 and other MBLs. 
Scheme 2. Zn(II) ions coordinating a hydroxide ion to promote nucleophilic attack on a generic 























































In order to combat AMR toward β-lactams, scientists developed inhibitors to co-
prescribe with the antibiotics.10,11 The inhibitor preferentially binds to the β-lactamase 
enzyme allowing the antibiotic to kill the bacteria. For example, the drug Augmentin is a 
mixture of amoxicillin, a known β-lactam antibiotic and clavulanic acid, a clinically 
available β-lactamase inhibitor (Figure 2). Clavulanic acid binds preferentially to the β-
lactamase, preventing it from hydrolyzing amoxicillin, which allows the drug to bind to 
PBPs and kill the bacteria.10 Due to the structural similarities between clavulanic acid and 
β-lactam antibiotics, bacteria quickly developed resistance to Augmentin shortly after it 
was clinically introduced through genetic modifications of the enzyme active site.5,11 It is 
important that future potential inhibitors do not contain the same structural moieties as β-
lactam antibiotics. In the case of MBLs, like NDM-1, there are no known clinical 
inhibitors.9 
 Yang and coworkers strived to synthesize broad-spectrum inhibitors of MBLs that 
mimic the transition state of the hydrolysis of β-lactam antibiotics, but do not contain the 
lactam ring.12 Instead, β-phospholactams contain a similar moiety but with a 
phosphonamide functionality where the oxygen atoms of the PO2 moiety coordinate to the 
Zn(II) in the active site.12 This group developed a 10-step synthesis to form a novel β-
phospholactam compound that mimics the tetrahedral intermediate formed with during 
hydrolysis of β-lactam antibiotics (Figure 3). At a concentration of 100 μM, 1 inhibited 
several MBLs with a maximum of 94% percent inhibition. The compound also inhibited 

















NDM-1, the MBL that can hydrolyze carbapenems, with 53% inhibition at 100 μM, which 
is a promising development in the search for MBL inhibitors.12 Despite their potential 
inhibitory properties, β-phospholactams require many steps for their synthesis, and it is 
difficult to modify the outlined synthesis to make a large library of compounds with 
varying functionality. In contrast to β-phospholactams, acyclic phosphonamides have not 
been evaluated as MBL inhibitors, however they have been shown to bind to human 
metallo-enzymes.13,14,15 Stein and co-workers studied phosphonamides as inhibitors of 
zinc-containing, human matrix metalloproteinases (MMPs), specifically stromelysin-1. In 
order for an inhibitor to be considered effective, the Ki defined as the concentration of 
inhibitor needed to produce half maximum inhibition, needs to be in the nM to very low 
μM range; the inhibitor they investigated was highly effective with a Ki = 5 nM (Figure 
Figure 3. Proposed β-phospholactam mimics the tetrahedral intermediate of a carbapenem coordinated 




























Figure 4. Phosphonamide inhibitor of Zn(II) dependent metallo-proteins16 
2 
 6 
4).16 They also discovered that once the inhibitor is bound in the active site of the enzyme, 
the phosphonate hydroxyl group acts as the hydroxide ion displacing the activated water 
molecule, which could contribute to the effectiveness of the compound.17 The Sawa group 
designed syntheses of phosphonamide inhibitors that allowed them to create a minimum of 
5 variations of the same core compound in minimal synthetic steps (Figure 5).18 They 
developed inhibitors with Ki values of 4.59, 5.20, and 5.05 nM for three different MMPs, 
which shows the high efficacy of the compounds.18 They also determined the compounds 
are highly stable. Their concentrations in human plasma were observed to remain at 100% 
after 60 minutes despite phosphonamide compounds being notoriously unstable in the 
human body.19 Phosphonamides are easier to synthesize than β-phospholactams and 
similarly to 1, they mimic the tetrahedral intermediate formed when antibiotics are 
hydrolyzed by MBLs. In addition, as explained previously, they are potent inhibitors of 
other Zn(II) dependent metallo-proteins.17,18 These qualities make phosphonamides 
excellent candidates as potential MBL inhibitors. The goal of this research is to develop a 
highly efficient synthetic strategy that is easily reproducible to create a library of 
phosphonamide compounds to serve as potential inhibitors of MBLs to combat the 








R1 = Me, Et, Ph
R2 = Me, Ph
R3 = H, n-hexyl, CH2Ph, CH2CH2Ph
R4 = H, Me, CH2-iPr
Figure 5. Various synthesized phosphonamide inhibitors18 
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Chapter 2: Strategy 
A single synthetic plan is utilized to create the compounds in Figure 6 in order to 
utilize a short and efficient synthesis that can be modified slightly to form compounds with 
various functionalities. The amino acid D-Proline is a consistent functional group among 
all of the target compounds and was chosen because if it were to arrange itself in the active 
site as we predict, it is likely the stereochemistry will allow the carboxylic acid to be 
positioned near a Zn(II) ion allowing for coordination. This coordination stabilizes the 
compound within the active site, so it remains bound for extended periods of time. In 
addition, the variable side chain can be functionalized to increase that stability by 












































3. n = 1














potentially creating Van der Waals interactions, pi-pi stacking and hydrogen bonding 
between the inhibitor and the enzyme. Polar side chains such as the morpholine group in 
compound 6 and the nitro group in compound 8 can hydrogen bond with amino acids like 
lysine and arginine, which are positively charged at pH 7. The proton bonded to the 
nitrogen of the aniline side chain in compound 5 can interact with negatively charged 
amino acid side chains like glutamate and aspartate. Other compounds like 9 have smaller 
side chains that keep their molecular weight low and could allow for a better fit of the 
inhibitor in the active site. Compounds 10 and 11 both contain fluorine like many other 
pharmaceuticals. The high stability of the carbon-fluorine bond allows for a slower 
metabolism of the drug. In addition, adding a carbon-fluorine bond to a compound 
increases its lipophilicity by increasing its hydrophobicity.20 Compounds 1, 2, 5, 8, and 11 
contain aromatic rings that may potentially allow for pi-pi stacking with amino acids like 
phenylalanine and tyrosine. In addition to varying the R side chain, the vinyl group of 
compound 7 can be further functionalized to create greater variation. All of these 
interactions help stabilize the inhibitor-enzyme complex and increase binding affinity. 
Michaelis-Arbuzov chemistry is used as an efficient method for the synthesis of these 
compounds with miscellaneous R groups (Scheme 3). The synthetic plan for these 
compounds is outlined in Scheme 3. Arbuzov reactions are performed neat and usually 
 9 
involve simple purification techniques, like distillation, to obtain the desired product. With 
the many different phosphonates made using Michaelis-Arbuzov chemistry, the remaining 
steps of the syntheses are also the same for each compound. After formation and 
purification of the diethoxy phosphonate 13, treatment with NaOH leads to 
monodealkylation through an SN2 reaction to form 14. Once that forms, chlorination using 
(COCl)2 creates a phosphonochloridate intermediate, which is used without further 
purification. D-proline ethyl ester hydrochloride pretreated with Et3N serves as a 
nucleophile and attacks the phosphonochloridate. The product is then deprotonated again 
with Et3N to form 15 in 4 steps overall (Scheme 3). This synthesis would be appealing to 
pharmaceutical companies as it requires minimal steps and allows for wide-ranging 
functionality at the R position. 













1. (COCl)2,  DMF
     CH2Cl2 30 m r.t.
2.D-Pro ethyl ester, Et3N














Chapter 3: Results and Discussion 
 The synthesis of compound 1 began with an Arbuzov reaction using 16 (Scheme 
4). In this reaction, the lone pair on the phosphorous of 12 attacks the carbon attached to 
the bromine of 16 and the bromide anion leaves. It then attacks the carbon next to the 
oxygen of the phosphonium ion 18 and the electrons move to satisfy the positive charge on 
the phosphorous, forming bromoethane as a side product that evaporates due to the high 
temperature of the reaction (Scheme 5). Initially, this reaction was performed on a much 
smaller scale in comparison to the procedure from which it was adapted, which proved to 
be an challenge during the work-up. The literature work-up for this compound begins with 















Scheme 4. Michaelis-Arbuzov reaction to form phosphonate 1723 
12 16 17 





















12 16 18 
17 
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16 using a 50/50 ethanol/water mixture. On such a small scale, these purification 
techniques were ineffective, so column chromatography was used. Unfortunately, 17 
degrades on silica so the product was lost. When performed on larger scales, cooling the 
reaction overnight causes starting material 16 to precipitate, then the literature work up 
could be followed. On a 10 gram scale, or higher, the precipitation technique was highly 
effective, yielding 17 in 73% yield. 
 There were multiple attempts to form the monoethyl ester 19 following 
synthesis of 17 (Scheme 6). These reactions proceed through an SN2 mechanism where the 
nucleophile, either I-, or OH-, attacks the methylene carbon of the ethoxy group of 17 and 
the phosphonate anion 20 leaves (Scheme 7). Due to the instability of dianions, only one 
of the ethoxy groups is dealkylated. After acidification and extraction, 19 forms. 








































Unfortunately, the NMR spectra confirmed that neither of these reactions formed the 
desired product. 
Coward and Malachowski developed a synthesis that forms the 
phosphonochloridate directly from the diester in moderate yields using PCl5 which would 
shorten the overall synthesis (Scheme 8).25 After chlorination, 21 would be used without 
further purification in the substitution reaction to form the final product. 31P NMR was 
used to determine the purity of the product because there is only one signal per phosphorous 
species present. The NMR of the purest product obtained showed 3 signals at 4.45, 37.85 
and 42.67 ppm, indicating it was impure.  The literature explained that this product was 
used without further purification because of its high reactivity, so the impure product was 
used in anticipation that the final product could be isolated after the substitution reaction 
(Scheme 9).25 The final reaction was attempted with the impure starting material and 
resulted in a complex mixture containing 5 different phosphorous species as there were 5 
signals in the 31P NMR spectrum. The separation was difficult, and the isolated amounts 
were so low that it was clear new methods were necessary to form 22.  
 

















86 oC, 20 h













D-Pro ethyl ester  HCl, Et3N





Shen and coworkers patented a reaction that used t-BuNH2 to form the monoester 
product in high yields, but they showed that it is important for the starting material to be 
the dimethyl ester and not the diethyl ester that was previously formed (Scheme 10).26  
They explained that the methyl t-BuNH2+ salt that forms is highly stable whereas the ethyl-
containing salt does not form. The initial reaction is an Arbuzov reaction with 23 instead 
of 12 (Scheme 4). This reaction was much less efficient than the initial reaction described 
in Scheme 4, as 24 was isolated in 19% yield in comparison to 17 which was isolated in 
73% yield. After the formation of 24, t-BuNH2 was used to form the monomethyl ester 25 
(Scheme 10). The 1H NMR spectrum showed peaks indicating the desired product was 
made, but there were several impurities present making it impossible to determine the yield. 




























45 oC, 3 d
2. Acidifcation
yield unknown
Scheme 10. Arbuzov reaction between 16 and 23 followed by formation of the monodealkylated product 25 
with t-BuNH226 





All of the reactions used to form compound 25 proceed through an SN2 mechanism 
as discussed previously. The monodealkylation using NaOH yielded starting material only, 
while the products of the reactions using NaI and LiBr could not be determined by 
examining the NMR spectra (Table 1). 




As a result of the low yielding Arbuzov reaction as well as the inability to form 
pure 24 in high yields, other methods were investigated. For reasons not fully understood, 
Hirshmann and coworkers had more success making the monodealkylated product when 
the amine was protected with a Cbz group as opposed to a phthalimide group. As a result, 
a new synthetic strategy was developed and outlined in Scheme 12. First, 17 was efficiently 
deprotected using hydrazine monohydrate in ethanol at room temperature and free amine 
26 was isolated in 84% yield. Next, 26 was protected using benzyl chloroformate (CbzCl) 
to yield 27 in unexpectedly low yield. Finally, the monoethyl ester product 28 was formed 
using NaOH in moderate yield.   
Conditions Outcome 
2M NaOH, r.t., 18 h No reaction 
NaI, acetone, reflux, 24 h SM + product unable to be determined 













Scheme 11. Formation of monomethyl ester product25,26 
24 25 
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After determining an efficient synthetic pathway to form the monoester product 28, 
the focus was shifted to developing a synthetic plan for target compound 3. As depicted in 
Scheme 13, 29 was dissolved in 12 and heated to form phosphonate 30 in 83% yield. Unlike 
17, this product does not degrade on silica and can be further purified using column 
chromatography. The next steps, outlined in Scheme 14, involve removal of the 
phthalimide protecting group to form 31 in 58% yield followed by reprotection with Cbz-
Cl to form 32 in 37% yield. Although removal of phthalimide groups from amines 
generally proceeds in moderate yields, Cbz-protections of amines using similar reaction 
conditions are generally reported to be much higher yielding than 37%.28 It is hypothesized 




















































Scheme 13. Arbuzov reaction to form phosphonate 3027 
29 12 30 
 16 
running the reaction for longer periods of time, but these reaction conditions were never 
explored. Monodealkylation of 32 with 2M NaOH to form 33 was successful with a lower 
yield of 26% in comparison to compound 28 (Scheme 11). 
The synthesis of compound 5 was next. Unlike for 1 and 2, we did not use Arbuzov 
chemistry to form diethyl ester 3c. Instead, the first reaction to form the diethyl ester was 
to expose the acetal functional group of diethyl phosphonate 34 to HCl and heat in order 
to form aldehyde 35 (Scheme 15). Once formed, a reductive amination with aniline was 
used to form 36 in a 52% yield (Scheme 16). Multiple reaction conditions were explored 
to form the monodealkylated product 37 (Scheme 17). The mono-dealkylation was 
attempted with NaOH, LiBr, and NaI, but these reactions yielded complex mixtures, and 


















































 In response to the numerous failed attempts at forming the monoethyl ester 37, 
formation of the di-dealkylated product 38 was attempted (Scheme 18). It was 
hypothesized that after formation of 38, a bulky protecting group like a benzyl or tert-butyl 
group, could be used to favor monoprotection and give 39, which would then could be 
converted to the required phosphonochloridate. Acidic conditions were used to attempt 
formation of 38 through a hydrolysis pathway as opposed to the SN2 reaction used to form 





1. AcOH, 3Å M.S., aniline
r.t., 4 h
2. NaBH3CN
    MeOH
























Scheme 18. Proposed synthesis of 39 using a bulky protecting group27 
36 38 39 














hydrolysis, so the protection reaction was not performed. Due to financial constraints there 
was no further progress made toward final compound 5.  
 For our synthesis of final compound 6, we also chose an alternative to an Arbuzov 
reaction. Matveeva and coworkers developed a green chemistry reaction where diethyl 
vinyl phosphonate (40) and morpholine are stirred in water at room temperature to give 41 
(Scheme 19).32 After lyophilization, the product is isolated in quantitative yield. These 
reaction conditions were used due to the high efficiency of this reaction, and the fact that 
the starting material had been previously purchased. In this reaction, morpholine serves as 
a nucleophile and attacks the vinyl group of 40 which deprotonates water to form a 
hydroxide ion. The hydroxide ion deprotonates the morpholine in 42 in order to form 41 
(Scheme 20). This reaction is highly efficient as a result of the electrophilicity of the vinyl 
phosphonate (40). After completing this reaction, the results were in accordance with the 

































Scheme 20. Mechanism of reaction to form 41 
41 40 42 
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There are no literature procedures describing the formation of monoethyl ester 43 
(Scheme 21). Similar to previous reactions, NaOH was used for monodealkylation, but the 
work up was different. Acidification to pH = 1 forms a salt that is impossible to extract 
from the aqueous layer. Instead, the reaction mixture was acidified to pH = 6 to form a 
zwitterion and then lyophilization was used to remove water. The resulting solid was 
dissolved in CH2Cl2 and any remaining solid was filtered. Product 43 was successfully 
formed in moderate yields. The presence of product was confirmed using 1H NMR 
spectroscopy. The integration of the methyl peak is 3 instead of 6 and there is a broad 
singlet downfield that corresponds to the OH attached to the phosphorous. It is important 
to note that due to the slow conformational changes of the morpholine ring, the NMR peaks 
corresponding to protons attached to it are very broad, but their integrations and chemical 
shifts align with predicted spectra. The 13C NMR contained the appropriate number of 
peaks and the HRMS also confirmed that the product was made.  
The monodealkylated products 52 through 56 were formed using the optimized 
synthetic strategy outlined in Scheme 22. Compound 40 is commercially available. 
Compounds 40 and 48 through 51 were formed in quantitative yields using Arbuzov 
chemistry followed by vacuum distillation to remove excess triethyl phosphite.33–36  The 
















use of NaOH to synthesize 53 and 54 from 48 and 49, respectively, has been previously 
reported in the literature and the NMR data collected aligned with the data reported.37,38  
Compounds 52 and 55 have not been reported in the literature and they were 
synthesized in 94% and 95% yields respectively. Not only is the developed reaction 
successful in forming compounds never made before, but the high yields indicate it is 
highly efficient. The products’ structures were confirmed using 1H NMR and 13C NMR. 
The 31P NMR spectra showed one phosphorous signal indicating the products are pure and 
HRMS reported masses were consistent with the calculated molecular weights.   
 Compound 56 was formed using the same reaction, but with some modifications. 
Essentially, the monodealkylation reaction with NaOH was performed twice. The first 
reaction rid the reaction mixture of any excess 12, but 51 remained unreacted because it is 
insoluble in NaOH. The unreacted 51 was recovered and reacted with NaOH a second time 
at higher temperatures to improve solubility. Pure 56 was isolated in 97% yield further 
validating the high efficiency of this reaction. This monodealkylation reaction is highly 













44. R = p-NO2PhCH2
45. R = CH2CH3
46. R = CH2PhF5
47. R = p-CF3PhCH2
R Br + P
O
O O 160 oC
18 h
52. R = CH=CH2, 94%
53. R = p-NO2PhCH2, 95%
54. R = CH2CH3, 53%
55. R = CH2PhF5, 95%
56. R = p-CF3PhCH2, 97%
40. R = CH=CH2
48. R = p-NO2PhCH2
49. R = CH2CH3
50. R = CH2PhF5
51. R = p-CF3PhCH2
100%
NaOH
Scheme 22. Formation of 52 through 56 using Arbuzov chemistry followed by monodealkylation  
12 
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 A chlorination reaction with (COCl)2 and catalytic DMF followed by a substitution 
reaction with protected D-Proline and Et3N were used to form the final compounds (Scheme 
23). The chlorination reaction was allowed to run for only 30 minutes to prevent side 
product formation. In an attempt to optimize reaction conditions, the solvents, temperatures 
and reaction times of the substitution reaction were varied as well as the initial starting 
materials. The outcomes of these reactions are outlined in Table 2. 
Table 2. Product yield of chlorination and substitution reactions with various reaction conditions 
Starting material Solvent Temperature Reaction time Yield 
R = CH2CH2NHCbz (28) THF 0 oC à r.t. 4 h 0% 
R = CH2CH2NHCbz (28) CH2Cl2 0 oC à r.t. 18 h 0% 
R = CH2NHCbz (33) CH2Cl2 0 oC à r.t. 18 h 0% 
R = CH2CH3 (54) CH2Cl2 0 oC à r.t 18 h 0% 
R = CH2CH3 (54) CH2Cl2 0 oC à 40 oC 18 h 0% 
R = CH2PhF5 (55) CH2Cl2 0 oC à 40 oC 18 h 5% 
R = p-NO2PhCH2 (53) MeCN 0 oC à 80 oC 18 h 33% 
 
 
Scheme 23. Chlorination reaction followed by substitution reaction with variable starting materials, 






1. (COCl)2, DMF (cat.)
CH2Cl2
r.t., 30 m












 The chlorination and substitution reactions using 28 yielded no desired product. 
The reaction time was increased to 18 hours promote product formation. The 
nucleophilicity of D-Proline is lowered due to steric hinderance so giving it more time to 
react should be beneficial. In addition, the solvent was changed to CH2Cl2 because D-
Proline is only marginally soluble in THF. After changing these reaction conditions, there 
was still no product formation observed. TLC analysis showed that other products had 
formed, but the different products were unable to be isolated. A similar attempt was made 
to form 3 and 9, but the reactions yielded no desired products. In both reactions, there were 
still a large number of spots on TLC and many smeared together making separation 
impossible. In addition, the same starting material was used again, but the reaction was 
heated to 40 oC. Although no product was isolated, the spots on TLC became more resolved 
and there were fewer. Next, in an attempt to form 10, 55 was used and the reaction was 
heated to 40 oC for 18 hours. The desired product was isolated in 5% yield, which made 
NMR analysis challenging. Unfortunately, the product became contaminated and further 
purification of such a small amount lead to loss of product. When synthesizing 8, the 
reaction was performed in MeCN in order for the mixture to be heated to 80 oC to further 
promote product formation. These reaction conditions produced pure final product in 33% 
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yield. Using these reaction conditions, the remaining final products were formed (Scheme 
24).  
 Final product 8 was isolated as a 1:1 mixture of diastereomers in 33% yield. It was 
determined there was a mixture of diastereomers as there were double the number of 
expected peaks in the 1H and 13C NMR spectra. The presence of diastereomers was 
established with variable temperature 31P NMR spectroscopy. The product was dissolved 
in DMSO and an NMR spectrum was taken at 25 oC showing two signals at 25.25 and 
25.67 ppm. Next, the sample was slowly heated to 80 oC, and as the heat increased, it would 
be expected that the two peaks would coalesce if rotamers were present. Instead, they 
resolved into sharper, more distinct peaks supporting the presence of diastereomers, which 















Figure 5. Diastereomers 8a and 8b 
8a 8b 
Scheme 24. Chlorination and substitution reactions to form target compounds in reported 
yields22,25 
28. R = CH2CH2NHCbz
33. R = CH2NHCbz
52. R = CH=CH2
53. R = p-NO2PhCH2
54. R = CH2CH3
55. R = CH2PhF5






1. (COCl)2, DMF (cat.)
   DCM
   r.t., 30 m
2. D-proline ethyl ester  HCl, Et3N
ACN







4. R = CH2CH2NHCbz, 0%
3. R = CH2NHCbz, 0%
7. R = CH=CH2, 17%
8. R = p-NO2PhCH2, 33%
9. R = CH2CH3, 47%
10. R = CH2PhF5, 20%
11. R = p-CF3PhCH2, 15%
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A 1H{13C} HSQC was performed to determine which proton signals correlated to 
the signals from the carbon attached to the phosphorous (Figure 8). Using the information, 
it was determined that the peaks corresponding to the protons at e with JPH = 20.0 Hz and 
in the 1H NMR correlated to the peaks corresponding to carbon e with JPC-values of 130.0 
Hz, which represent the carbons attached directly to the phosphorous in each diastereomer. 
This information helped conclude the expected J-values for the protons closest to the 
phosphorous as well as the carbons directly attached. A TOCSY and a NOESY were 
performed to determine the reasons the protons e on each diastereomer exhibited different 
splitting patterns, but nothing conclusive was found. Finally, HRMS reported a single 
molecular weight corresponding to what is expected for compound 8, which supports the 
conclusion that the two 31P NMR peaks are indicative of diastereomers.  
All of the phosphonamide products shown in Scheme 24 were formed as a 1:1 
mixture of diastereomers as supported by the 31P NMR spectra, save compound 11. It is 
unknown as to why 11 was isolated as a single diastereomer, but the spectral data supports 
the absence of a mixture. Each of the products was confirmed using 1H, 13C, and 31P NMR 
spectroscopy in addition to HRMS. Compounds 3 and 4 were not made due to time and 
financial constraints, but are future targets for this project. Compounds 7, 10 and 11 were 
formed in lower yields compared to other compounds that were successfully made. 
Compounds 7 and 11 form in addition to several side products and thus are each difficult 


















Figure 6. Final compound 8 
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not optimized. It is proposed that compound 9 was made in the highest yield because 54 is 
the simplest starting material.  
The reaction outlined in Scheme 24 was also performed with the morpholine 
monoethyl ester 43 to form target compound 6, but it was unsuccessful. The NMR 
indicated that the desired product was made, but it was difficult to purify. Instead of the 
typical chlorination and substitution reactions, target compound 7 was reacted with 
morpholine, similarly to the reaction described in Scheme 19. Compound 7 was dissolved 
in water and treated with morpholine, but after 24 hours, no reaction had taken place 
according to TLC. This is likely a result of the phosphonamide vinyl group of 7 being much 
less electrophilic than that of phosphonate 40. A microwave reactor was used to promote 
product formation, and after 1 hour at 100 oC pure product was isolated in 74% yield 
(Scheme 25). In the future, this reaction can be used to efficiently increase diversity in the 
final library of compounds by varying the nucleophiles reacting with the vinyl 
phosphonamide.  
 In the future, this 4-step optimized synthetic plan can be used to expand the library 
of the 6 successfully synthesized target compounds. Final compounds 3 and 4 can be 
synthesized and then deprotected to form the free amine and add 4 new compounds to the 
library. In addition, target compound 7 can be reacted with a variety of nucleophiles and a 
microwave reactor can be used to improve yield. The nitro group on compound 8 can be 



















reduced to an amine and achieve different functionality as well. Each of the successfully 
formed target compounds will be analyzed against Gram-negative bacteria known to 
express class B b-lactamases using minimum inhibitory concentration (MIC) assays in 
collaboration with Dr. Robert Bonomo at Case Western Reserve University. If the 
compounds inhibit bacterial growth in low concentrations, they will be tested in vitro 
against isolated MBLs. 
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Chapter 4: Experimental 
 
I. Reagents and Solutions 
All reagents and solvents employed were purchased from Acros Organics Ltd. 
(Hampton, NH), Alfa-Aesar Chemicals. (Haverhill, MA), MilliporeSigma Chemical 
Company (St. Louis, MO), Oakwood Products, Inc. (Estill, SC), or TCI American 
Chemicals. (Portland, OR) unless specifically stated. 
All reagents and solvents were of American Chemical Society (ACS) grade and 
were used without further purification unless otherwise stated. All reactions were 
performed under a positive pressure of nitrogen using oven or flame-dried glassware. All 
organic solvents were dried over molecular sieves prior to use. Solvents for anhydrous 
reactions were dried over sieves prior to use. The removal of solvent in vacuo refers to 
evaporation under reduced pressure below 40˚C using a rotary evaporator followed by 
evacuation (< 0.1 mm Hg) to a constant sample mass. Unless otherwise stated, solutions of 
NH4Cl, NaHCO3, HCl, H2SO4, and NaOH refer to aqueous solutions. Brine refers to a 
saturated solution of NaCl. 
 
II. Purification techniques 
All reactions and fractions obtained from column chromatography were monitored 
by thin layer chromatography (TLC) using glass-backed plates (1.5 x 5 cm) pre-coated with 
silica gel containing and UV florescent indicator. Compounds were visualized by exposing 
the plates to UV light, or through iodine staining, unless otherwise stated. All mobile 
phases used are indicated in their respective procedures. 
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III. Instrumentation for Compound Characterization 
Nuclear magnetic resonance (NMR) spectra were obtained on a Varian Mercury 
400, 500 MHz spectrometers. 1H NMR and 13C NMR (101 MHz) chemical shifts are 
reported in parts per million (ppm) relative to tetramethylsilane as the internal standard and 
coupling constant values are given in [Hz]. 31P NMR (202.3 MHz) chemical shifts are 
relative to phosphoric acid (0 ppm). Proton spectra were processed and baseline corrected 
with a Bernstein polynomial function. Carbon and phosphorous spectra were processed 
with line broadening of 1 Hz or 3 Hz and baseline corrected with a Bernstein polynomial 
or Spline function. The following abbreviations are given for spin multiplicity: s = singlet, 
d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dt = doublet of triplets, ddd 
= doublets of doublets of doublets, td = triplet of doublets, qd = quartet of doublets, dbm = 
doublet of broad multiplets. Additional assignments were made using homonuclear 
correlation spectroscopy (g-COSY), total correlation spectroscopy (TOCSY), 
heteronuclear single quantum coherence spectroscopy (gHSQC), heteronuclear multiple 
bond correlation spectroscopy (gHMBC), and nuclear Overhauser effect spectroscopy 
(NOESY). All literature compounds had 1H NMR spectra consistent with the assigned 
structures. 
 
IV. Experimental Procedures and Data  
 
Phosphonamide, P-[(2-(4-morpholinyl)ethyl-D-proline ethyl ester]-, monoethyl ester 
(6) 
This compound was prepared with modifications made to the 
procedure from Matveeva et al.32 Compound 7 (0.050 g, 0.190 







flask, and morpholine (0.016 mL, 0.190 mmol) was added. The reaction was placed in a 
microwave reactor, pre stirred for 1 minute and then heated to 100 oC and left to react for 
1 hour. After cooling, the reaction was lyophilized and the crude product was purified using 
column chromatography (SiO2, gradient 0.05 to 1% MeOH in CH2Cl2) to yield the product 
as an orange oil. (0.490 g, 74%): 1H NMR (400 MHz, CD3OD) δ 1.24 – 1.33 (m, 12H, 
POCH2CH3 and COCH2CH3), 1.91 – 2.29 (m, 12H, proline CH2CH2 and PCH2CH2), 2.48 
(bm, 8H, morpholine NCH2), 2.57 – 2.79 (m, 4H, PCH2CH2), 3.24 (m, 4H, proline NCH2), 
3.70 (q, 8H, morpholine OCH2, J = 4.6 Hz), 3.87 – 4.05 (m, 2H, OCH2CH3), 4.14 – 4.19 
(m, 6H, OCH2CH3), 4.22 (dt, 1H, proline NCH, J = 8.3, 3.3 Hz), 4.34 (dt, 1H, proline 
NCH, J = 8.3, 3.3 Hz); 13C NMR (101 MHz, CD3OD) δ 13.06 (d, JPC = 3.5 Hz), 15.13 (d, 
6.4 Hz), 15.20 (d, 5.6 Hz), 21.91 (d, 131.6 Hz), 22.65 (d, 131.5 Hz), 24.85 (d, 7.7 Hz), 
24.92 (d, 7.2 Hz), 30.66 (d, 25.1 Hz), 30.73 (d, 25.4 Hz), 46.10 (d, 5.2 Hz), 46.15 (d, 4.6 
Hz), 51.33, 51.37, 52.81, 52.90, 59.33 (d, 66.9 Hz), 59.60 (d, 66.1 Hz), 59.73 (d, 22.1 Hz), 
59.78 (d, 21.7), 60.68, 60.79, 66.18, 66.26, 174.14, 174.37 (5 carbons discernable due to 
spectral overlap); 31P NMR (202.3 MHz, CDCl3) δ 30.62, 31.42; HRMS (ES+) calcd for 
C15H29N2O5P 349.1891 found C15H30N2O5P 349.1892 [M+H]+. 
 
Phosphonamide, P-[vinyl-D-proline ethyl ester]-, monoethyl ester (7) 
 This compound was prepared with modifications made to the procedures 
from Hirschmann et al.  and Malachowski et al.22,25 Compound 52 (0.155 
g, 1.14 mmol) was dissolved in CH2Cl2 (5 mL) and catalytic amounts of 
DMF were added. Next, (COCl)2 (0.110 mL, 1.25 mmol) was added dropwise and the 








proline ethyl ester (0.202 g, 1.14 mmol) was dissolved in MeCN (5 mL), Et3N (0.480 mL, 
3.41 mmol) was added and that reaction was cooled to 0 oC. After 30 minutes, the initial 
reaction was concentrated in vacuo, redissolved in MeCN (5 mL) and added dropwise to 
the second reaction at 0 oC. The combined reactions were slowly brought to r.t. and then 
heated to 80 oC for 18 hours. Next, the formed salt was removed using vacuum filtration, 
the reaction was concentrated in vacuo and then purified by column chromatography (SiO2, 
100% EtOAc) to yield the product, a 1:1 mixture of diastereomers, as a yellow oil. (0.050 
g, 17%): 1H NMR (400 MHz, CDCl3) δ 1.24 – 1.34 (m, 12H, POCH2CH3 and COCH2CH3), 
1.81 – 2.21 (m, 8H, proline CH2CH2), 3.17 – 3.28 (m, 4H, NCH2), 3.90 – 3.99 (m, 1H, 
OCH2CH3), 4.04 – 4.10 (m, 1H, OCH2CH3), 4.12 – 4.19 (m, 6H, OCH2CH3), 4.26 – 4.34 
(m, 2H, NCH), 5.93 – 6.01 (m, 2H, PCH), 6.06 – 6.26 (m, 4H, NCH2); 13C NMR (101 
MHz, CDCl3) δ 14.14, 16.22 (d, JPC = 3.4 Hz), 16.29 (d, 3.4 Hz), 20.55 (d, 7.5 Hz), 25.25 
(d, 7.6 Hz), 31.20 (d, 7.8 Hz), 31.28 (d, 7.4 Hz), 46.16 (d, 5.6 Hz), 46.43 (d, 5.2 Hz), 59.58 
(d, 5.4 Hz), 59.71 (d, 5.3 Hz), 59.77 (d, 6.8 Hz), 60.35 (d, 5.4 Hz), 60.87 (d, 7.2 Hz), 126.60 
(d, 171.9 Hz), 126.63 (d, 171.8 Hz), 133.20, 133.22, 174.01, 174.29; 31P NMR (202.3 MHz, 
CDCl3) δ 18.32, 18.93; HRMS (ES+) calcd for C11H20NO4P 262.1206 found C11H21NO4P 
262.1208 [M+H]+. 
 
Phosphonamide, P-[(3-nitrophenyl)methyl-D-proline ethyl ester]-, monoethyl ester 
(8) 
This compound was prepared with modifications made to the 
procedures from Hirschmann et al.  and Malachowski et al.22,25 








(5 mL) and catalytic amounts of DMF were added. Next, (COCl)2 (0.200 mL, 2.24 mmol) 
was added dropwise and the reaction was stirred at r.t. for 30 minutes. While that was 
stirring, in a separate RBF, D-proline ethyl ester (0.326 g, 1.84 mmol) was dissolved in 
MeCN (10 mL), Et3N (0.800 mL, 5.51 mmol) was added and that reaction was cooled to 0 
oC. After 30 minutes, the initial reaction was concentrated in vacuo, dissolved in MeCN (5 
mL) and added dropwise to the second reaction at 0 oC. The combined reactions were 
slowly brought to r.t. and then heated to 80 oC for 18 hours. Next, the reaction was 
concentrated in vacuo and purified by column chromatography (SiO2, gradient from 5:1 
EtOAc/Hexanes to 100% EtOAc) to yield the product, a 1:1 mixture of diastereomers, as 
a yellow oil. (0.241 g, 33%): 1H NMR (500 MHz, CDCl3) δ 1.24 (t, 6H, COCH2CH3, J = 
7.0 Hz), 1.29 (td, 6H, POCH2CH3, J = 7.2, 2.2 Hz), 1.73 – 2.22 (m, 9H, proline CH2CH2), 
2.89 – 3.02 (m, 2H, proline NCH2), 3.16 – 3.30 (m, 2H, proline NCH2), 3.21 (dd, 2H, 
PCH2, J = 20.0, 4.9 Hz), 3.38 (d, 2H, PCH2, J = 20.0 Hz), 3.77 – 3.87 (m, 1H, POCH2CH3), 
3.97 (m, 1H, NCH), 4.00 – 4.06 (m, 1H, POCH2CH3), 4.11 – 4.22 (m, 6H, COCH2CH3 
and POCH2CH3), 4.42 (m, 1H, NCH), 7.45 (q, 2H, ArH, J = 7.2 Hz), 7.73 (m, 1H, ArH), 
8.08 (m, 2H, ArH), 8.13 (m, 1H, ArH), 8.24 (m, 1H, ArH); 13C NMR (101 MHz, CDCl3) 
δ 14.11, 14.19, 16.10 (d, JPC = 11.7 Hz), 16.17 (d, 11.7 Hz), 25.08 (d, 19.0 Hz), 25.16 (d, 
29.5 Hz), 30.85 (d, 28.8 Hz), 30.92 (d, 29.0 Hz), 33.06 (d, 130.0 Hz), 34.17 (d, 130.0 Hz), 
46.65 (d, 41.1 Hz), 46.61 (d, 42.1 Hz), 59.84, 59.91, 60.07 (d, 8.7 Hz), 60.12 (d, 8.9 Hz), 
60.71, 60.78, 61.01, 61.18, 121.52 (d, 22.7 Hz), 121.55 (d, 23.0 Hz), 124.36 (d, 52.4 Hz), 
124.43 (d, 52.7 Hz), 129.06 (d, 28.8 Hz), 129.09 (d, 29.0 Hz), 134.87 (d, 40.7 Hz), 134.95 
(d, 40.7 Hz), 136.10 (d, 24.7 Hz), 136.16 (d, 24.7 Hz), 148.13, 174.13; 31P NMR (202.3 
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MHz, CDCl3) δ 25.25, 25.67; HRMS (ES+) calcd for C16H23N2O6P 371.1364 found 




Phosphonamide, P-[ethyl-D-proline ethyl ester]-, monoethyl ester (9) 
 This compound was prepared with modifications made to the procedures 
from Hirschmann et al.  and Malachowski et al.22,25 Compound 54 (1.00 g, 
4.20 mmol) was dissolved in CH2Cl2 (10 mL) and catalytic amounts of DMF 
were added. Next, (COCl)2 (0.400 mL, 4.60 mmol) was added dropwise and the reaction 
was stirred at r.t. for 30 minutes. While that was stirring, in a separate RBF, D-proline ethyl 
ester (0.750 g, 4.20 mmol) was dissolved in MeCN (10.0 mL) and Et3N (1.75 mL, 12.6 
mmol) was added and that reaction was cooled to 0 oC. After 30 minutes, the initial reaction 
was concentrated in vacuo, dissolved in MeCN (10 mL) and added dropwise to the second 
reaction at 0 oC. The combined reactions were slowly brought to r.t. then heated to 80 oC 
for 18 hours. Next, the reaction was concentrated in vacuo and purified by column 
chromatography (SiO2, 10% EtOAc/Hex to 100% EtOAc) to yield the product, a 1:1 
mixture of diastereomers, as an orange oil. (0.895 g, 47%): 1H NMR (400 MHz, CDCl3) δ 
1.03 – 1.12 (dt, 3H, PCH2CH3, J = 19.7, 7.7 Hz), 1.09 – 1.17 (dt, 3H, PCH2CH3, J = 19.7, 
7.7 Hz), 1.20 – 1.28 (m, 12H, POCH2CH3 and COCH2CH3), 1.56 – 2.18 (m, 12H, proline 
CH2CH2 and PCH2CH3), 3.13 – 3.26 (m, 4H, NCH2), 3.75 – 3.85 (m, 1H, POCH2CH3), 
3.97 – 4.17 (m, 7H, POCH2CH3 and COCH2CH3), 4.19 – 4.23 (dt, 1H, NCH, J = 8.5, 3.4 







JPC = 6.0 Hz), 6.24 (d, 6.0 Hz), 14.14 (bs), 16.25 (d, 6.5 Hz), 16.29 (d, 6.5 Hz), 18.22 (d, 
133.5 Hz), 18.98 (d, 133.5 Hz), 25.18 (d, 6.7 Hz), 25.24 (d, 6.7 Hz), 31.04 (d, 7.4 Hz), 
31.27 (d, 7.4 Hz), 46.32 (d, 5.0 Hz), 46.51 (d, 5.0 Hz), 58.99, 59.06, 59.64 (d, 12.0 Hz), 
59.69 (d, 12.0 Hz), 60.79, 60.84, 174.22, 174.45; 31P NMR (202.3 MHz, CDCl3) δ 34.68, 
35.28; HRMS (ES+) calcd for C11H22NO4P 264.1365 found C11H23NO4P 264.1365 
[M+H]+. 
 
Phosphonamide, P-[(pentafluorophenyl)methyl-D-proline ethyl ester]-, monoethyl 
ester (10) 
This compound was prepared with modifications made to the 
procedures from Hirschmann et al.  and Malachowski et al.22,25 
Compound 55 (0.446 g, 1.50 mmol) was dissolved in CH2Cl2 (5 
mL) and catalytic amounts of DMF were added. Next, (COCl)2 (0.150 mL, 1.70 mmol) 
was added dropwise and the reaction was stirred at r.t. for 30 minutes. While that was 
stirring, in a separate RBF, D-proline ethyl ester (0.270 g, 1.50 mmol) was dissolved in 
MeCN (6 mL), Et3N (0.630 mL, 4.50 mmol) was added and that reaction was cooled to 0 
oC. After 30 minutes, the initial reaction was concentrated in vacuo, dissolved in MeCN (5 
mL) and added dropwise to the second reaction at 0 oC. The combined reactions were 
slowly brought to r.t. then heated to 80 oC for 18 hours. Next, the reaction was concentrated 
in vacuo and purified by column chromatography (SiO2, 100% EtOAc) to yield the product, 
a 1:1 mixture of diastereomers, as a yellow oil. (0.122 g, 20%): 1H NMR (500 MHz, 
CDCl3) δ 1.20 – 1.32 (m, 12H, POCH2CH3 and COCH2CH3), 1.85 – 2.23 (m, 8H, proline 










(m, 8H, POCH2CH3 and COCH2CH3), 4.36 (dt, 1H, J = 8.4, 3.2 Hz); 13C NMR (101 MHz, 
CDCl3) δ 14.01, 16.01 (d, JPC = 12.4 Hz), 16.08 (d, 12.4 Hz), 20.64 (d, 130.0 Hz), 21.31 
(d, 130.0 Hz), 25.00 (d, 19.0 Hz), 25.08 (d, 19.0 Hz), 30.90 (d, 25.0 Hz), 30.97 (d, 25.0 
Hz), 46.33 (d, 16.4 Hz), 46.38 (d, 16.4 Hz), 60.03 (d, 11.0 Hz), 60.01 (d, 11.0 Hz), 61.01, 
61.07, 61.16, 107.45 (m), 136.20 (m), 138.70 (m), 141.17 (m), 143.98 (m), 146.55 (m), 
173.84, 174.11; 31P NMR (202.3 MHz, CDCl3) δ 22.79, 23.85; HRMS (ES+) calcd for 
C16H19F5NO4P 416.1045 found C16H20F5NO4P 416.1050 [M+H]+. 
 
Phosphonic acid, P-[[4-(trifluoromethyl)phenyl]methyl-D-proline ethyl ester]-, 
monoethyl ester (11) 
 This compound was prepared with modifications made to the 
procedures from Hirschmann et al.  and Malachowski et al.22,25 
Compound 56 (0.542 g, 2.02 mmol) was dissolved in CH2Cl2 (8 
mL) and catalytic amounts of DMF were added. Next, (COCl)2 (0.190 mL, 2.22 mmol) 
was added dropwise and the reaction was stirred at r.t. for 30 minutes. While that was 
stirring, in a separate RBF, D-proline ethyl ester (0.359 g, 2.02 mmol) was dissolved in 
MeCN (10 mL), Et3N (0.850 mL, 6.06 mmol) was added and that reaction was cooled to 
0 oC. After 30 minutes, the initial reaction was concentrated in vacuo, dissolved in MeCN 
(8 mL) and added dropwise to the second reaction at 0 oC. The combined reactions were 
slowly brought to r.t. then heated to 80 oC for 18 hours. Next, the reaction was 
concentrated in vacuo and purified by column chromatography (SiO2, 100% EtOAc) to 
yield the product as a yellow oil. (0.125 g, 15%): 1H NMR (400 MHz, CDCl3) δ 1.26 (m, 








CH2CH2, J = 13.0, 8.0 Hz), 2.93 (m, 2H, NCH2), 3.33 (s, 1H, PCH2), 3.38 (s, 1H, PCH2), 
3.81 (m, 1H, POCH2CH3), 4.03 (m, 1H, POCH2CH3), 4.18 (q, 2H, COCH2CH3, J = 7.3 
Hz), 4.39 (dt, 1H, NCH, J = 8.7, 3.5 Hz), 7.52 (m, 4H, ArH); 13C NMR (101 MHz, 
CDCl3) δ 14.20, 16.20 (d, JPC = 6.4 Hz), 25.39 (d, 6.7 Hz), 30.88 (d, 6.7 Hz), 34.46 (d, 
127.6 Hz), 47.40 (d, JFC = 1.9 Hz), 59.74 (d, 6.4 Hz), 60.00 (d, 4.4 Hz), 61.09, 125.10, 
130.40 (d, 5.3 Hz), 137.31 (d, 9.1 Hz), 174.18; HRMS (ES+) calcd for C17H23F3NO4P 
394.1394 found C17H24F3NO4P 394.1395  [M+H]+.  
 
 
Phosphonic acid, P-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-, diethyl ester 
(17) 
This compound was prepared according to the procedure from 
Graillot et al.23 Compound 16 (10.0 g, 39.4 mmol) was dissolved 
in 12 (35.0 mL, 197 mmol). The reaction was stirred at reflux for 
18 hours then distilled under vacuum to remove excess 12. Dissolution with a 50/50 
water/ethanol mixture followed by vacuum filtration to remove excess starting material 
yielded pure product as a viscous yellow liquid. (8.90 g, 73%): 1H NMR (500 MHz, CDCl3) 
δ 1.31 (m, 6H, CH3), 2.22 (m, 2H, NCH2), 3.97 (m, 2H, PCH2) 4.12 (m, 4H, OCH2CH3), 
7.74 (m, 2H, ArH), 7.85 (m, 2H, ArH); 31P NMR (202.3 MHz, CDCl3) δ 26.74. 
 
Phosphonic acid, P-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-, dimethyl ester 
(24) 
This compound was made according to the procedure form Shen et 
al.26 16 (2.08 g, 7.87 mmol) was dissolved in 23 (9.30 mL, 39.4 
















remove excess 23. Further purification was done using column chromatography (SiO2, 
100% EtOAc) to yield the product as a pale yellow liquid. (2.20 g, 19%): 1H NMR (500 
MHz, CDCl3) δ 2.22 (m, 2H, NCH2), 3.76 – 3.78 (s, 6H, OCH3), 3.97 (m, 2H, PCH2), 7.74 
(m, 2H, ArH), 7.85 (m, 2H, ArH); 31P NMR (202.3 MHz, CDCl3) δ 29.33. 
 
Phosphonic acid, P-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-, monomethyl 
ester (25) 
This compound was made according to the procedure from Shen et 
al.26 Compound 24 (0.250 g, 0.883 mmol) and tBuNH2 (5.00 mL, 
47.8 mmol) were combined and heated to 50 oC for 24 hours while 
stirring. The reaction was filtered using vacuum filtration and concentrated in vacuo to 
remove excess tBuNH2. The solid was dissolved in MeOH then DOWEX resin (1.00 g) 
was added and the solution was stirred for 1 hour followed by filtration and concentration 
in vacuo. The orange solid was recrystallized in EtOAc/Hexanes and the product was 
isolated as white crystals using vacuum filtration. (0.050 g, 21%): 1H NMR (400 MHz, 
CDCl3) δ 2.18 (m, 2H, PCH2), 3.75 (s, 3H, OCH3), 3.95 (m, 2H, NCH2), 7.73 (m, 2H, 
ArH), 7.85 (m, 2H, ArH). 
 
Phosphonic acid, P-(2-aminoethyl)-, diethyl ester (26) 
This compound was prepared according to the procedure from 
Hirschmann et al.22 Compound 17 (8.40 g, 26.9 mmol) was dissolved in 
EtOH and Hydrazine monohydrate (13.1 mL, 269 mmol) was added. The reaction was 














without heating to yield the product as a clear liquid. (4.10 g, 84%): 1H NMR (500 MHz, 
CDCl3) δ 1.34 (t, 6H, OCH2CH3, J = 6.7 Hz), 1.92 (dt, 2H, PCH2, J = 17.8, 7.0 Hz), 3.03 
(dt, 2H, NCH2, J = 17.4, 7.0 Hz), 3.98 (m, 4H, OCH2CH3). 
 
 
Carbamic acid, N-[2-(ethoxyhydroxyphosphinyl)ethyl]-, phenylmethyl ester (27) 
This compound was prepared according to the procedure from 
Hirschmann et al.22 Compound 26 (4.10 g, 22.0 mmol) was 
dissolved in CH2Cl2 and the mixture was cooled to 0 oC. Benzyl chloroformate (3.40 mL, 
23.7 mmol) and Et3N (4.50 mL, 32.4 mmol) were added. The reaction was allowed to warm 
to r.t. and stirred overnight. It was diluted with CH2Cl2 and washed with 2M H2SO4 (3 x 
15 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. The product 
was further purified by column chromatography (SiO2, 100% EtOAc to 10% 
MeOH:CH2Cl2) to yield a yellow oil. (1.80 g, 27%): 1H NMR (500 MHz, CDCl3) δ 1.30 
(t, 6H, OCH2CH3, J = 7.1 Hz), 2.00 (dt, 2H, PCH2, J = 17.7, 6.8 Hz), 3.44 (m, 2H, NCH2), 
4.07 (m, 3H, OCH2CH3), 5.08 (bs, 2H, benzyl CH2), 5.55 (bs, 1H, NH), 7.33 (m, 5H, ArH); 
31P NMR (202.3 MHz, CDCl3) δ 29.36. 
 
Carbamic acid, N-[2-(ethoxyhydroxyphosphinyl)ethyl]-, phenylmethyl ester (28) 
This compound was prepared according to the procedure from 
Hirschmann et al.22 Compound 27 (0.800 g, 2.50 mmol) was 
dissolved in 2M NaOH (45.0 mL) and stirred vigorously for 18 hours at r.t. The reaction 














H2SO4 and extracted with CH2Cl2 (3 x 25 mL) and EtOAc (3 x 20 mL). The organic layers 
were combined and dried with MgSO4 then concentrated in vacuo to yield the product as a 
pale-yellow liquid. (0.405 g, 55%): 1H NMR (500 MHz, CDCl3) δ 1.32 (t, 3H, OCH2CH3, 
J = 7.1 Hz), 2.01 (dt, 2H, PCH2, J = 18.5, 6.8 Hz), 3.49 (dt, 2H, NCH2, J = 18.5, 6.3 Hz), 
4.09 (p, 2H, OCH2CH3, J = 7.3 Hz), 5.10 (bs, 2H, benzyl CH2), 5.37 (bs, 1H, NH), 7.35 
(m, 5H, ArH), 10.47 (bs, 1H, OH); 31P NMR (202.3 MHz, CDCl3) δ 34.71. 
 
Phosphonic acid, P-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-, diethyl ester 
(30) 
This compound was prepared according to the procedure from Clinch et 
al.27 29 (3.00 g, 12.5 mmol) was dissolved 12 triethyl phosphite (10.0 
mL, 62.5 mmol) and stirred at reflux for 16 hours. Vacuum distillation 
was used to remove excess 12 and the product was further purified using column 
chromatography (SiO2, 100% EtOAc) to yield a clear oil. (3.10 g, 83%): 1H NMR (500 
MHz, CDCl3) δ 1.37 (m, 6H, OCH2CH3), 3.02 (m, 2H, PCH2), 4.10 (m, 4H, OCH2CH3), 
7.35 (m, 4H, ArH). 
 
Phosphonic acid, P-(2-aminomethyl)-, diethyl ester (31) 
This compound was prepared with modifications made to the procedure 
from Hirschmann et al.22 Compound 30 (5.03 g, 16.9 mmol) was dissolved 
in absolute EtOH (100 mL) and hydrazine monohydrate (8.25 mL, 169 mmol) was added. 
The reaction continued for 18 hours at r.t. The resulting solid was removed using vacuum 














a yellow oil. (1.64 g, 58%): 1H NMR (500 MHz, CDCl3) δ 1.35 (m, 6H, OCH2CH3), 
3.00(m, 2H, PCH2), 4.15 (m, 4H, OCH2CH3); 31P NMR (202.3 MHz, CDCl3) δ 25.57. 
 
 
Carbamic acid, N-[2-(diethoxyphosphinyl)methyl]-, phenylmethyl ester (32) 
This compound was prepared with modifications made to the 
procedure from Hirschmann et al.22 Compound 31 (1.64 g, 9.80 
mmol) was dissolved in CH2Cl2 and the solution was cooled to 0 
oC. After it was cooled, benzyl chloroformate (1.54 mL, 10.8 mmol) and Et3N (2.05 mL, 
14.7 mmol) were added. The reaction was allowed to slowly warm to r.t. and stirred 
overnight. After concentrating the reaction in vacuo, column chromatography (SiO2, 100% 
EtOAc) was used to yield the product as a yellow oil. (1.09 g, 37%): 1H NMR (500 MHz, 
CDCl3) δ 1.32 (t, 6H, OCH2CH3, J = 7.7 Hz), 3.63 (m, 2H, PCH2), 4.13 (p, 4H, OCH2CH3, 
J = 7.3 Hz), 5.08 (bs, 1H, NH), 5.14 (s, 2H, benzyl CH2), 7.37 (m, 5H, ArH). 
 
Carbamic acid, N-[2-(ethoxyhydroxyphosphinyl)methyl]-, phenylmethyl ester (33) 
This compound was prepared with modifications made to the 
procedure from Hirschmann et al.22 Compound 32 (1.06 g, 3.53 
mmol) was dissolved in 2M NaOH (45.0 mL) and the reaction was 
stirred vigorously at r.t. for 18 hours. The reaction was then extracted with CH2Cl2 (2 x 20 
mL) and acidified to pH = 1 with 2M H2SO4. Following acidification, the solution was 
extracted with CH2Cl2 (3 x 30 mL) and EtOAc (3 x 20 mL). The organic layers were 
















yellow oil. (0.248 g, 26%): 1H NMR (500 MHz, CDCl3) δ 1.31 (t, 3H, OCH2CH3, J = 7.3 
Hz), 3.64 (d, 2H, PCH2, J = 11.6 Hz), 4.12 (p, 2H, OCH2CH3, J = 7.4 Hz), 5.14 (s, 2H, 




Phosphonic acid, P-(2-oxoethyl)-, diethyl ester (35) 
 
This compound was prepared according to the procedure from Markey et 
al.29 Compound 34 (1.90 mL, 7.90 mmol) was added to a round bottom 
flask with 2% HCl (10.0 mL, 35.4 mmol). The reaction was heated to 100 oC and stirred 
for 4 hours. After cooling, the reaction was saturated with NaCl and extracted with CH2Cl2 
(2 x 20 mL). The organic layer was washed with NaHCO3, water, and brine then dried with 
MgSO4 and concentrated in vacuo to yield the product as a clear liquid. (0.780 g, 55%): 1H 
NMR (500 MHz, CDCl3) δ 1.36 (m, 6H, OCH2CH3), 3.11 (m, 2H, PCH2), 4.18 (m, 4H, 
OCH2CH3), 9.68 (bs, 1H, OCH); 31P NMR (202.3 MHz, CDCl3) δ 18.85.  
 
Phosphonic acid, P-[2-(phenylamino)ethyl]-, diethyl ester (36) 
This compound was prepared according to the procedure from Baxter 
et al.30 Compound 35 (0.300 g, 1.60 mmol) was dissolved in MeOH, 
and then aniline (0.150 mL, 1.60 mmol) was added followed by acetic 
acid (102 μL, 1.60 mmol) and 3Å mol sieves. After stirring for 4 hours at r.t., NaBH3CN 
(0.101 g, 3.20 mmol) was added and the reaction was stirred for an additional 18 hours. 
The reaction was concentrated in vacuo and the solid was dissolved in EtOAc then washed 










vacuo. The resulting solid was further purified by column chromatography (SiO2, 2% Et3N 
in EtOAc) to yield the product as off white crystals. (0.410 g, 81%): 1H NMR (500 MHz, 
CDCl3) δ 1.35 (m, 6H, OCH2CH3), 2.08 (dt, 2H, PCH2, J = 17.5, 6.9 Hz), 3.46 (dt, 2H, 
NCH2, J = 17.5 6.9 Hz), 4.12 (m, 4H, OCH2CH3), 6.63 (m, 2H, ArH), 6.74 (tt, 1H, ArH, 
J = 7.3, 1.1 Hz), 7.20 (m, 2H, ArH); 31P NMR (202.3 MHz, CDCl3) δ 29.84. 
 
Phosphonic acid, P-[2-(4-morpholinyl)ethyl]-, diethyl ester (41) 
This compound was prepared according to the procedure from 
Matveeva et al.32 Compound 40 (4.20 mL, 24.3 mmol) was dissolved 
in water and morpholine (2.10 mL, 24.3 mmol) was added. The reaction 
was stirred at r.t. for 1 hour followed by lyophilization to yield pure product as a clear 
liquid. (6.10 g, 100%): 1H NMR (500 MHz, CDCl3) δ 1.33 (t, 6H, OCH2CH3, J = 6.9 Hz), 
1.97 (m, 2H, PCH2), 2.46 (bs, 4H, morpholine NCH2), 2.66 (q, 2H, PCH2CH2, J = 8.1 Hz), 
3.71 (bs, 2H, morpholine OCH2), 4.11 (m, 4H, OCH2CH3). 
 
Phosphonic acid, P-[2-(4-morpholinyl)ethyl]-, monoethyl ester (43) 
This compound was made with modifications to the procedure from 
Hirschmann et al.22 Compound 41 (3.00 g, 11.9 mmol) was dissolved in 
2M NaOH and stirred vigorously at r.t. for 18 hours. The solution was 
extracted with CH2Cl2 (2 x 30 mL) and brought to pH = 6 with 2M H2SO4 and then 
lyophilized to yield white solid. The solid was stirred in CH2Cl2 (200 mL) for 1 hour and 
the mixture was filtered using vacuum filtration. The CH2Cl2 was dried using MgSO4 and 












MHz, CDCl3) δ 1.22 (t, 3H, CH2CH3, J = 7.2 Hz), 1.99 (bm, 2H, PCH2), 2.95 (bs, 4H, 
morpholine NCH2), 3.10 (bs, 2H, PCH2CH2), 3.88 (bm, 6H, morpholine OCH2 and 
POCH2CH3), 9.53 (bs, 1H, OH); 13C NMR (101 MHz, CDCl3) δ 16.83 (d, JPC = 7.0 Hz), 
22.43 (d, 129.4), 51.76, 53.60, 60.14 (d, 5.6), 64.67; 31P NMR (202.3 MHz, CDCl3) δ 
18.65; HRMS (ES+) calcd for C10H18NO4P 224.1043 found C18H19NO4P 224.1052 
[M+H]+. 
 
Phosphonic acid, P-[(3-nitrophenyl)methyl]-, diethyl ester (48) 
This compound was made in accordance to the procedure from Appari 
et al.33 Compound 44 (2.80 g, 13.0 mmol) and 12 (11.1 mL, 65.0 
mmol) were stirred at reflux for 30 minutes. Excess 12 was removed 
using vacuum distillation and the product was isolated as a dark red liquid. (3.50 g, 100%): 
1H NMR (500 MHz, CDCl3) δ 1.34 (td, 6H, OCH2CH3, J = 7.0, 0.9 Hz), 3.21 (s, 1H, 
PCH2), 3.26 (s, 1H, PCH2), 4.08 (m, 4H, OCH2CH3), 7.50 (t, 1H, ArH, J = 8.1 Hz), 7.67 
(dbm, ArH, 1H, J = 7.4 Hz), 8.11 (dbm, 1H, ArH, J = 8.3 Hz), 8.61 (bm, 1H, ArH). 
 
Phosphonamide, P-[vinyl]-, monoethyl ester (52) 
This compound was made with modifications made to the procedure from 
Hirschmann et al.22 Compound 40 (0.200 g, 1.22 mmol) was dissolved in 
2M NaOH (5 mL) and stirred vigorously for 18 hours at room temperature. The reaction 
was washed with CH2Cl2 (2 x 10 mL) then the aqueous layer was acidified to pH = 2 
with 2M H2SO4. After acidification, the solution was extracted with CH2Cl2 (2 x 10 mL) 











concentrated in vacuo to yield pure product as a yellow oil. (0.155 g, 94%): 1H NMR 
(400 MHz, CDCl3) δ 1.33 (m, 3H, OCH2CH3), 4.03 (m, 2H, OCH2CH3), 6.00 – 6.33 (m, 
3H, vinyl CH2 and CH), 12.63 (bs, 1H, OH); 13C NMR (101 MHz, CDCl3) δ 16.21 (d, 
JPC = 6.2 Hz), 61.71 (d, 6.4 Hz), 125.23 (d, 188.0 Hz), 134.69; 31P NMR (202.3 MHz, 
CDCl3) δ 19.21; HRMS (ES+) calcd for C4H9O3P 135.0211 found C4H10O3P 135.0212 
[M+H]+. 
Phosphonic acid, P-[ethyl]-, diethyl ester (49) 
This compound was made according to the procedure form Huang et al.34 
Compound 45 (0.700 mL, 9.18 mmol) and 12 (15.0 mL, 91.8 mmol) were 
combined and stirred at reflux overnight. Fractional distillation was used to separate the 
product from the starting materials as a clear oil in quantitative yield: 1H NMR (500 MHz, 
CDCl3) δ 1.12 (dtd, 3H, PCH2CH3, J = 20.0, 7.5, 1.6 Hz), 1.31 (td, 3H, OCH2CH3, J = 7.0, 
1.61 Hz), 1.76 (m, 2H, PCH2CH3 ), 4.09 (m, 4H, OCH2CH3). 
 
Phosphonic acid, P-[(pentafluorophenyl)methyl]-, diethyl ester (50) 
This compound was made according to the procedure form Wang et 
al.35 Compound 46 (0.600 mL, 3.83 mmol) and 12 (2.00 mL, 11.5 
mmol) were combined and stirred at reflux for 12 hours. Excess 12 was 
removed using vacuum distillation to yield pure product as a yellow oil. (1.20 g, 100%): 
1H NMR (500 MHz, CDCl3) δ 1.30 (t, 6H, OCH2CH3, J = 7.0 Hz), 3.19 (m, 1H, PCH2), 
3.24 (m, 1H, PCH2), 4.13 (m, 4H, OCH2CH3). 
 














This compound was made according to the procedure from Skropeta 
et al.36 47 (0.500 g, 2.09 mmol) was dissolved in 12 (7.00 mL, 41.8 
mmol) and the reaction was heated to reflux for 18 hours. The 
reaction was cooled, and vacuum distillation was used to remove excess 12. The product 
was isolated as a clear liquid in quantitative yield: 1H NMR (400 MHz, CDCl3) δ 1.31 
(dt, 6H, OCH2CH3, J = 7.0, 0.5 Hz), 3.16 (s, 1H, PCH2), 3.22 (s, 1H, PCH2), 3.99 – 4.14 
(m, 4H, OCH2CH3), 7.40 (dd, 2H, ArH, J = 8.0, 2.0 Hz), 7.55, (d, 2H, ArH, J = 8.0 Hz) 
 
Phosphonic acid, P-[(3-nitrophenyl)methyl]-, monoethyl ester (53) 
This compound was made with modifications made to the procedure 
from Hirschmann et al.22 Compound 48 (3.50 g, 12.8 mmol) was 
dissolved in 2M NaOH (175 mL) and stirred vigorously for 48 hours at 
r.t.. The reaction was extracted with CH2Cl2 (2 x 35 mL) and acidified to pH = 2 using 2M 
H2SO4. The acidified solution was extracted with CH2Cl2 (3 x 40 mL) and EtOAc (3 x 25 
mL) and the combined organic layers were dried using MgSO4 and concentrated in vacuo. 
The resulting product was an orange powder. (3.00 g, 95%): 1H NMR (500 MHz, CDCl3) 
δ 1.25 (t, 3H, OCH2CH3, J = 6.9 Hz), 3.16 (s, 1H, PCH2), 3.22 (s, 1H, PCH2), 3.98 (m, 2H, 
OCH2CH3), 7.49 (t, 1H, ArH, J = 8.4 Hz), 7.71 (dbm, 1H, ArH, J = 7.4 Hz), 8.10 (dbm, 
1H, ArH, J = 8.4 Hz), 8.15 (m, 1H, ArH), 11.68 (bs, 1H, OH). 
 
Phosphonic acid, P-[ethyl]-, monoethyl ester (54) 
This compound was made with modifications made to the procedure from 















NaOH (30 mL) and the reaction was stirred vigorously at r.t. overnight. The resulting 
solution was extracted with CH2Cl2 and then acidified to pH = 2 with 2M H2SO4. The 
acidified solution was extracted with CH2Cl2 (2 x 20 mL) and EtOAc (2 x 20 mL). The 
combined organic layers were dried using MgSO4 and concentrated in vacuo to yield the 
product as a yellow oil. (0.720 g, 53.4%): 1H NMR (500 MHz, CDCl3) δ 1.14 (dt, 3H, 
PCH2CH3, J = 20.1, 7.7 Hz), 1.33 (t, 3H, OCH2CH3, J = 7.2 Hz), 1.75 (dq, 2H, PCH2CH3, 
J = 19.0, 7.6 Hz), 4.09 (pd, 4H, OCH2CH3, J = 7.2, 0.8 Hz) 11.75 (bs, 1H, OH). 
 
Phosphonic acid, P-[(pentafluorophenyl)methyl]-, monoethyl ester (55) 
This compound was made with modifications made to the procedure 
from Hirschmann et al.22 Compound 50 (1.50 g, 4.70 mmol) was 
dissolved in 2M NaOH (50 mL) and the reaction was stirred vigorously 
at r.t. for 48 hours. The reaction was then extracted with CH2Cl2 (2 x 20 mL) and acidified 
to pH = 1 with 2M H2SO4. After acidification, the solution was extracted with CH2Cl2 (2 
x 30 mL) and EtOAc (2 x 30 mL). The combined organic layers were dried using MgSO4 
and concentrated in vacuo to yield the product as a yellow oil. (1.30 g, 95%): 1H NMR 
(500 MHz, CDCl3) δ 1.30 (t, 3H, OCH2CH3, J = 6.9 Hz), 3.19 (s, 1H, PCH2), 3.24 (s, 1H, 
PCH2), 4.08 (m, 4H, OCH2CH3), 12.06 (bs, 1H, OH); 31P NMR (202.3 MHz, CDCl3) δ 
23.57; HRMS (ES+) calcd for C9H8F5NO4P 291.0208 found C9H9F5NO4P 291.0209 
[M+H]+. 
 










This compound was made with modifications made to the procedure 
from Hirschmann et al.22 Compound 51 was dissolved in 2M NaOH 
(150 mL) and stirred at room temperature for 48 hours. The reaction 
was stopped and extracted with CH2Cl2 (2 x 25 mL). The CH2Cl2 was then concentrated 
in vacuo and redissolved in 2M NaOH (25 mL). This reaction was heated to 90oC for 18 
hours. After cooling to room temperature, the reaction was extracted with CH2Cl2 (2 x 15 
mL) and then acidified to pH = 2 with 2M H2SO4. After the acidification, the aqueous 
solution was extracted with CH2Cl2 (2 x 20 mL) and EtOAc (2 x 20 mL). The organic 
layers were combined and dried with MgSO4 then concentrated in vacuo to yield the 
product as an off white powder (0.542 g, 97% yield): 1H NMR (500 MHz, CDCl3) δ 1.21 
(t, 3H, OCH2CH3, J = 7.1 Hz), 3.08 (s, 1H, PCH2), 3.12 (s, 1H, PCH2), 3.87 (m, 2H, 
OCH2CH3), 7.40 (d, 2H, ArH, J = 8.0 Hz), 7.56 (d, 2H, ArH, J = 8.0 Hz); 13C NMR (101 
MHz, CDCl3) δ 16.09 (d, JPC = 6.6 Hz), 32.97 (d, 137.5 Hz), 61.98 (d, 7.1 Hz), 125.30 (d, 
3.5 Hz), 128.99 (qd, J = 32.7, 3.8 Hz), 130.24 (d, 6.3 Hz), 135.77 (d, 9.3 Hz); 31P NMR 
(202.3 MHz, CDCl3) δ 27.56; HRMS (ES+) calcd for C10H12F3O3P 269.0553 found 



















































Figure 7: 1H NMR (400 MHz, CD3OD) for 6 
 48 
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